Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Cancer stem cells (CSCs) exhibit enhanced chemo/radiotherapy resistance, and their survival following cancer treatment is believed to be responsible for tumor recurrence and metastasis. Thus, understanding the mechanisms through which CSCs survive conventional chemotherapy is essential for identification of new therapeutic strategies to prevent tumor relapse. Our findings that ovarian CSCs survive cisplatin treatment through elevated expression of polymerase η represent an opportunity to eradicate CSCs and improve the survival of ovarian cancer patients. In addition, identification of miR-93 as the regulator of polymerase η expression provides a target to increase the efficacy of cisplatin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, this DNA polymerase was shown to be induced in several human cell lines after treatment with chemotherapeutic agents in a p53-dependent manner, and was linked to acquired resistance to chemotherapy ( 24 , 25 ).”
From Predominant role of DNA polymerase eta and p53-dependent translesion synthesis in the survival of ultraviolet-irradiated human cells (2017) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The upregulation of miR-93, a microRNA that triggers pol η degradation, also enhanced the effect of cisplatin [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Experimental — accuracy not yet measuredIn the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells, which is evidenced in populations that resist cisplatin treatment [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The effect of cisplatin was enhanced when simultaneously depleting pol η in ovarian-cancer-cell models [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundDirect Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391 · cited 1×
“These cross-links block DNA replication and invoke apoptosis in rapidly dividing cells (5).”
BackgroundIdentification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293 · cited 15×
“Ovarian CSCs have been successfully isolated, based on the expression of distinctive cell surface markers CD44 and CD117 (18, 19), their ability to efflux the Hoechst 33342 fluorescent dye (Side population, SP) (20), the activity of ALDH (21), and their ability to grow as floating spheres in serum-free medium (19).”
BackgroundMethodInfluentialCancer Stem Cells: Models and Concepts
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.062105.204854 · Cited by 1,274 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundCancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171 · cited 1×
“Thus, this reduced expression of MCM7, probably due to relative quiescence of CSCs (49, 50), could be a contributor to the decreased expression of miR-93 in CSCs.”
BackgroundOvarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154 · cited 2×
“Cancer Chemother Pharmacol 39(3):245–253.”
BackgroundSide Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3557 · Cited by 947 · cited 1×
“Although MCM7 overexpression has been identified in various tumors and considered a bad prognostic indicator in prostate cancer (45, 46), MCM7 expression is lower in various CSCs, including SP of human lung cancer cells (47) and prostate cancer cells (48), as well as ALDH+ breast cancer cells (41).”
BackgroundMechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869 · cited 6×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
MethodInfluential
Cited by
Items 101–188 of 188
VSV based virotherapy in ovarian cancer: the past, the present and …future?
Orzechowska, B., Jędryka, M., Zwolińska, K., & Matkowski, R. (2017) · Journal of Cancer · doi:10.7150/jca.19473 · Cited by 21
“showed recently that ovarian CSCs have intrinsically enhanced Pol η-mediated translesion DNA synthesis (TLS) which permitting CSCs to survive cisplatin treatment and leading to tumor relapse [64].”
BackgroundZhang, H. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1768205 · Cited by 20
“The expression of Pol g is up-regulated in ovarian cancer stem cells; and Pol g could enhance TLS across cisplatin-induced DNA lesions and contributes to the survival of cancer stem cells upon treatment with cisplatin (Srivastava et al. 2015).”
BackgroundTranslesion DNA Synthesis and Reinitiation of DNA Synthesis in Chemotherapy Resistance
Shilkin, E. S., Boldinova, E. O., Stolyarenko, A. D., Гончарова, Р. И., Chuprov‐Netochin, R. N., Smal, M. P., & Makarova, А. V. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920080039 · Cited by 18
Chen, Y., Zhang, Y., Chen, Y., Ragaller, F., Liu, M., Corvigno, S., Dahlstrand, H. M., Carlson, J. W., Chen, Z., Näsman, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236291 · Cited by 18
High Risk α-HPV E6 Impairs Translesion Synthesis by Blocking POLη Induction
Wendel, S. O., Snow, J. A., Bastian, T., Brown, L. E., Hernandez, C., Burghardt, E., Kahn, A., Murthy, V., Neill, D., Smith, Z. C., et al. (2020) · Cancers · doi:10.3390/cancers13010028 · Cited by 17
“Further, POLH overexpression can drive chemo-resistance [34].”
BackgroundWilson, D. M., Duncton, M. A. J., Chang, C., Luo, C. L., Georgiadis, T. M., Pellicena, P., Deacon, A. M., Gao, Y., & Das, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778925 · Cited by 20
“Suppression of POLH expression also enhances cisplatin-induced apoptosis of cancer stem cells isolated from both ovarian cancer cell lines and primary tumors (10).”
BackgroundThe Role of E3 Ligase Pirh2 in Disease
Daks, A. A., Fedorova, O., Parfenyev, S. E., Nevzorov, I. A., Shuvalov, O. Y., & Barlev, N. A. (2022) · Cells · doi:10.3390/cells11091515 · Cited by 21
CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target
Feng, X., Bai, X., Ni, J., Wasinger, V. C., Beretov, J., Zhu, Y., Graham, P., & Li, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00557 · Cited by 15
“It was demonstrated that cisplatin treatment could enrich CSCs in ovarian cancer (21, 22), and these ovarian CSCs could survive cisplatin cytotoxicity through the enhancement of miR-93 expression (23).”
BackgroundDecoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
Shafi, S., Khan, S. I., Hoda, F., Fayaz, F., Singh, A., Khan, M. A., Ali, R., Pottoo, F. H., Tariq, S., & Najmi, A. K. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200303124946 · Cited by 15
Mechanism of neem limonoids-induced cell death in cancer: Role of oxidative phosphorylation
Yadav, N., Kumar, S., Kumar, R., Srivastava, P., Sun, L., Rapali, P., Marlowe, T. A., Schneider, A., Inigo, J. R., O’Malley, J., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.11.028 · Cited by 17
“Current anticancer agents are unable to induce efficient cancer cell death as well as these agents also cause enrichment of cancer-initiating cells, which ultimately results in recurrence of cancer such as colon and ovarian cancers, and metastasis to distant sites [67, 68].”
BackgroundBostian, A. C. L., & Eoff, R. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00255 · Cited by 16
DNA repair gene expression is increased in HPV positive head and neck squamous cell carcinomas
Holcomb, A. J., Brown, L. E., Tawfik, O. W., Madan, R., Shnayder, Y., Thomas, S. M., & Wallace, N. A. (2020) · Virology · doi:10.1016/j.virol.2020.07.004 · Cited by 14
Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape
Zou, X., Zhao, Y., Liang, X., Wang, H., Zhu, Y., & Shao, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641937 · Cited by 12
“Besides, miR-93 increases the efficacy of cisplatin treatment via negatively regulating TLS DNA polymerase h (Pol h) in OC stem cells (CSCs) (35).”
BackgroundSonobe, R., Yang, P., Suzuki, M. M., Shinjo, K., Iijima, K., Nishiyama, N., Miyata, K., Kataoka, K., Kajiyama, H., & Kondo, Y. (2024) · Cancer Science · doi:10.1111/cas.16150 · Cited by 14
Minor Groove 3‐Deaza‐Adenosine Analogues: Synthesis and Bypass in Translesion DNA Synthesis
Malvezzi, S., Angelov, T., & Sturla, S. J. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604289 · Cited by 15
Metabolic modeling-based drug repurposing in Glioblastoma
Tomi-Andrino, C., Pandele, A., Winzer, K., King, J. R., Rahman, R., & Kim, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-14721-w · Cited by 11
Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass
Wilkinson, N. A., Mnuskin, K. S., Ashton, N. W., & Woodgate, R. (2020) · Cancers · doi:10.3390/cancers12102848 · Cited by 10
“Pol η, for example, seems to be involved in bypassing lesions caused by platinum-based chemotherapeutics such as cisplatin [97,136].”
BackgroundDNA polymerases in the risk and prognosis of colorectal and pancreatic cancers
Silvestri, R., & Landi, S. (2019) · Mutagenesis · doi:10.1093/mutage/gez031 · Cited by 12
Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors
Lengert, A. V. H., Pereira, L. D. N. B., Cabral, E. R. M., Gomes, I. N. F., de Jesus, L. M., Gonçalves, M. F. S., da Rocha, A. O., Tassinari, T. A., da Silva, L. S., Laus, A. C., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708245 · Cited by 11
“This mechanism has been connected to CDDP-resistance in several tumors, although it has still been little examined in TGCTs [28–31].”
BackgroundImplications of Translesion DNA Synthesis Polymerases on Genomic Stability and Human Health
Venkadakrishnan, J., Lahane, G. P., Dhar, A., Xiao, W., Bhat, K. M., Pandita, T. K., & Bhat, A. (2023) · Molecular and Cellular Biology · doi:10.1080/10985549.2023.2224199 · Cited by 13
Wilson, K. A., Holland, C. D., & Wetmore, S. D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1265 · Cited by 9
Yang, R., Wei, Z., & Wu, S. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14409 · Cited by 9
Srivastava, A. K., & Wang, Q.-E. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1043482 · Cited by 9
“Enforced expression of miR-93 in ovarian CSCs reduced Pol h expression and increased their sensitivity to cisplatin.(1) Therefore, targeting miR-93 could be a better approach to increase the efficacy of cisplatin treatment in ovarian cancer.”
BackgroundResultSelf-citationTargeting Genome Stability in Melanoma—A New Approach to an Old Field
Osrodek, M., & Woźniak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073485 · Cited by 11
Munafò, F., Nigro, M., Brindani, N., Manigrasso, J., Geronimo, I. M., Ottonello, G., Armirotti, A., & Vivo, M. D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115044 · Cited by 8
Targeting Cancer Stemness Using Nanotechnology in a Holistic Approach: A Narrative Review
Mitranovici, M.-I., Caravia, L. G., Moraru, L., & Pușcașiu, L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030277 · Cited by 7
“Another mechanism involved in chemoresistance is the overexpression of DNA repair mechanisms [65,66], such as base excision repair through increased poly (ADP-ribose) polymerase 1 (PARP1) activity [67] or decreased programmed cell death activity [68,69].”
miRNAs in radiotherapy resistance of cancer; a comprehensive review
Al-Hawary, S. I. S., Jasim, S. A., Altalbawy, F. M. A., Kumar, A., Kaur, H., Pramanik, A., Jawad, M. A., Alsaad, S. B., Mohmmed, K. H., & Zwamel, A. H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01329-2 · Cited by 9
Opportunities to advance cervical cancer prevention and care
Brooke, G., Wendel, S. O., Banerjee, A., & Wallace, N. A. (2024) · Tumour Virus Research · doi:10.1016/j.tvr.2024.200292 · Cited by 8
Cancer stem cell populations are resistant to 5-aminolevulinic acid-photodynamic therapy (5-ALA-PDT)
Rice, C. P. J., Chelakkot, V. S., Conohan, N. T., & Hirasawa, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-88173-3 · Cited by 7
Das, D., Duncton, M. A. J., Georgiadis, T. M., Pellicena, P., Clark, J., Sobol, R. W., Georgiadis, M. M., King-Underwood, J., Jobes, D. V., Chang, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316637 · Cited by 7
“The suppression of POLH expression also enhances the cisplatin-induced apoptosis of cancer stem cells isolated from both ovarian cancer cell lines and primary tumors [21].”
BackgroundA framework for mutational signature analysis based on DNA shape parameters
Karolak, A. M., Levatić, J., & Supek, F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262495 · Cited by 7
Liang, J., Liu, W., Zhang, T., Guo, D., Gong, J., & Yang, Z. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01089-y · Cited by 8
“The down-regulation of Rev1 expression in ovarian cancer cells also leads to a decrease in cisplatin-induced mutagenesis and drug resistance [166, 167].”
Zhuo, M., Gorgun, F. M., Tyler, D. S., & Englander, E. W. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12943 · Cited by 6
“…of the error-prone TLS polymerase eta and kappa that have been previously implicated in bypass synthesis of cisplatin crosslinks in different cell models (Roy & Scharer, 2016; Srivastava et al., 2015; Tomicic et al., 2014), while the expression of S phase replication proteins was reduced.”
BackgroundGorgun, F. M., Widen, S. G., Tyler, D. S., & Englander, E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701968 · Cited by 7
Xu, X., Jaberi‐Douraki, M., & Wallace, N. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158571 · Cited by 6
“Typically, tumors with elevated TLS polymerase expression are significantly less responsive to genotoxic therapies, resulting in worse prognoses for people with these tumors [1,14].”
BackgroundCanonical and Non-Canonical Roles of Human DNA Polymerase η
Bedaiwi, S., Usmani, A., & Carty, M. (2024) · Genes · doi:10.3390/genes15101271 · Cited by 5
“Consistent with a functional role for Pol η in the response of cancer cells to cisplatin, miRNA-mediated down-regulation of Pol η increases the sensitivity of ovarian cancer stem cells to cisplatin [30].”
BackgroundBRD9 inhibition as potential treatment option for testicular germ cell tumors
Hansen, A., Sanders, C., Fronhoffs, F., Funke, K., Kristiansen, G., & Schorle, H. (2025) · Andrology · doi:10.1111/andr.70038 · Cited by 7
Ma, X., Wang, C., Zhou, B. O., Cheng, Z., Mao, Z., Tang, T.-S., & Guo, C. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101861 · Cited by 5
“Emerging data show the importance of Pol η in in fl uencing the therapeutic outcome and chemoresistance of platinum-based anticancer drugs (20 – 22).”
Chang, C., Luo, C. L., Eleraky, S., Lin, A., Zhou, G., & Gao, Y. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102938 · Cited by 5
“Elevated Pol η expression has been found to help bypass cytarabine (81, 82).”
BackgroundLiu, X., Liang, D., Jiang, T., Dong, Q., & Yu, H. (2016) · Oncology and Translational Medicine · doi:10.1007/s10330-015-0119-3 · Cited by 5
Mandal, T., Shukla, D., Khan, M. M. A., Ganesan, S. K., & Srivastava, A. K. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02840-2 · Cited by 5
“TLS polymerase levels have previously been observed to be elevated in CSCs [13].”
InfluentialSelf-citationde Lima, A. B., Gonçalves, B. Ô. P., Moreira, M. P., Barros, B. A. F., Filho, A. L. D. S., Fialho, S. L., Braga, L. D. C., & Silva, L. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152322 · Cited by 5
Zhang, X., Chen, Q., Chen, J., Chun-ya, H., Mao, J., Dai, Y., Yang, X., Hu, W., Zhu, C., & Chen, B. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24103 · Cited by 5
“TLS polymerases confer drug resistance to some types of cancer such as glioma [18] and ovarian cancer [19].”
BackgroundSelf-citationCervical cancer cell lines are sensitive to sub-erythemal UV exposure
Gu, W., Sun, S., Kahn, A., Dacus, D., Wendel, S. O., McMillan, N. A. J., & Wallace, N. A. (2018) · Gene · doi:10.1016/j.gene.2018.11.079 · Cited by 4
Wang, W., Zhang, G., Yang, J., Gu, H., Ding, L., Yu, H., Yu, M., Cui, Q., Ji, X., & Li, M. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw119 · Cited by 4
Lung adenocarcinoma concomitant with xeroderma pigmentosum: a case report
Matsumoto, M., Kaneshiro, K., & Takatsuki, K. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02754-0 · Cited by 4
Wilson, K. A., Jeong, Y. E. R., & Wetmore, S. D. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp00481j · Cited by 3
Gallbladder Cancer: Current Treatment Options and Therapeutics
Taghizadieh, M., Seyedi, M., Azhdari, S., Dashti, F., Mirazimi, S. M. A., Baghi, H. B., Nahand, J. S., Aschner, M., & Mirzaei, H. (2023) · Springer eBooks · doi:10.1007/978-981-19-6442-8_1 · Cited by 3
DNA polymerases as chemotherapy targets: promise and challenges
Eckert, K. A., & Barnes, R. P. (2019) · Oncotarget · doi:10.18632/oncotarget.26572 · Cited by 3
Zhan, H., Guo, J., Song, Q., Tian, X., Wang, Z., Sha, X., & Liu, B. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01567 · Cited by 2
Xu, W., Kool, D., O’Flaherty, D. K., Keating, A. M., Sacre, L., Egli, M., Noronha, A. M., Wilds, C. J., & Zhao, L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00278 · Cited by 2
Saito, S., Wuputra, K., Kato, K., & Yokoyama, K. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822231-7.00002-3 · Cited by 3
Systematic analysis of DNA polymerases as therapeutic targets in pan-cancers
LI, Z., Lv, H., Zhang, F., ZHU, Z., GUO, Q., WANG, M., HUANG, C., Chen, L., ZHANG, W., LI, Y., et al. (2024) · Biocell · doi:10.32604/biocell.2023.031568 · Cited by 4
Bose, S., Saha, P., Alam, M. T., Chatterjee, B., Sarkar, M., Dixit, A. K., Kumar, D., Pathak, R., Tripathi, P. P., & Srivastava, A. K. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70037 · Cited by 4
Self-citationYu, F., Cao, Z., Xu, A., & Du, H. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113902 · Cited by 2
Tsao, W.-C., Buj, R., Aird, K. M., Sidorova, J. M., & Eckert, K. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251188 · Cited by 2
“DNA polymerase degradation in response to Ras in SV40 transformed cells is associated with altered replication fork dynamics DNA polymerase levels can be altered in human tumors (8); specifically, POLH is upregulated or amplified in melanoma, esophageal and ovarian cancer [28, 32, 53, 54], which contrasts with the HRa…”
BackgroundDNA Damage Responses, the Trump Card of Stem Cells in the Survival Game
Tayanloo-Beik, A., Hamidpour, S. K., Nikkhah, A., Arjmand, R., Mafi, A. R., Rezaei–Tavirani, M., Larijani, B. A., Gilany, K., & Arjmand, B. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_791 · Cited by 2
Prognostic and Predictive Significance of Base Excision Repair in Human Cancers
Ali, R., & Madhusudan, S. (2016) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814719735_0017 · Cited by 1
Application of Nano Drug Delivery Systems in Inhibition of Tumors and Cancer Stem Cells
Xiao, D., & Zhou, R. (2021) · Springer eBooks · doi:10.1007/978-981-16-2666-1_4 · Cited by 1
Yang, J. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155870 · Cited by 1
Determination of DNA lesion bypass using a ChIP-based assay
Wu, D., Banerjee, A. T., Cai, S., Li, N., Han, C., Bai, X., Zhang, J., & Wang, Q. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103230 · Cited by 2
Self-citationSrivast, A., Bose, S., Saha, P., Alam, M. T., Chatterjee, B., Sarkar, M., Dixit, A. K., Kumar, D., & Tripathi, P. P. (2023) · Research Square · doi:10.21203/rs.3.rs-3118868/v1 · Cited by 1
Wei, S. (2016) · Human Biology
Samuel, P. (2016) · Radar (Oxford Brookes University) · doi:10.24384/bhrw-wn75
Tsao, W.-C., Buj, R., Aird, K. M., Sidorova, J. M., & Eckert, K. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.01.180455
“Specifically, we and others have shown that Pol η mRNA and protein levels are increased in tumor cells in response to exogenous sources of replication stress (Ceppi et al. 2009; Srivastava et al. 2015; Lerner et al. 2017; Barnes et al. 2018).”
BackgroundInfluentialApplication of cancer stem cells in improving therapeutics
Jain, S., Raza, K., Agrawal, A. K., & Vaidya, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817846-1.00015-1
ROLE OF CANCER STEM CELLS IN OVARIAN CARCINOGENESIS
Gening, S., & Antoneeva, I. I. (2020) · Ulyanovsk Medico-biological Journal · doi:10.34014/2227-1848-2020-3-82-103
DNA repair | XPV Polymerase and the Bypass of Ultraviolet DNA Damage
Sabbioneda, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00130-4
Itoyama, M., Ohara, A., Yokoyama, K., Yamamoto, S., Kato, K., Mori, T., Igaki, H., Nakano, E., Yamazaki, N., Sunami, K., et al. (2023) · doi:10.22541/au.167905278.80731071/v1
Peng, C., Chen, Z., Wang, S., Wang, H., Qiu, W., Zhao, L., Xu, R., Luo, H., Chen, Y., Chen, D., et al. (2023) · doi:10.1158/0008-5472.c.6508311.v1
Zhang, J., Sun, W., Ren, C., Kong, X., Yan, W., & Chen, X. (2023) · doi:10.1158/0008-5472.c.6511202
Data from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment
Sekhar, K. R., & Freeman, M. L. (2023) · doi:10.1158/0008-5472.c.6628636.v1
Data from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment
Sekhar, K. R., & Freeman, M. L. (2023) · doi:10.1158/0008-5472.c.6628636
Cisplatina: uma visão bioquímica
Camargo, G., & Hassunuma, R. M. (2023) · doi:10.52050/9788579176166
Ma, X., Yang, F., Ma, K., Shen, H., Han, J., Wang, K., Yang, Y., Zhu, J., An, R., Wang, Q., et al. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250241
Self-citationHong, J., Yeom, M., Hwang, H.-Y., Mun, E., Woo, J.-H., Kim, Y., Shin, J., Lee, Y., Kim, D., Guengerich, F. P., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111551
Okraine, Y. V., de la Vega, M. B., Arbilla, S. V., Moyano, G., Bertolin, A. P., Pallarés, H. M., Wiesmüller, L., Mansilla, S. F., & Gottifredi, V. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07812-9
“For example, in cells that acquire resistance to cisplatin (CDDP), the levels of Pol η are frequently increased [14]; hence suggesting that excess TLS by Pol η protects cancer cells from CDDP-mediated cell killing.”
Zhang, Q., & Yu, Y. (2025) · Journal of Radiation Research · doi:10.1093/jrr/rraf057
Shruptha, P., Poyya, J., Vasudevan, T. G., & Satyamoorthy, K. (2025) · Epigenomics · doi:10.1080/17501911.2025.2595912 · Cited by 3
Helou, R. E. (2015) · theses.fr (ABES) · doi:10.70675/b8b014d8z89d6z430azbcdaz904de9456f21
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.730955
“An increased expression of Polη has impacted cisplatin therapy and survival time of patients with non–small-cell lung cancer, ovarian cancer, and metastatic gastric adenocarcinoma (Chin et al. 2008; Srivastava et al. 2015).”
khedmatgozar, M., Yazdi, F., Motlagh, F. R., Prasad, K., Islomov, S., Al-Khafaji, Z., Ali, A. F., Almalki, S. G., Salajegheh, P., & Rahmani, P. (2026) · Discover Oncology · doi:10.1007/s12672-026-05347-9
“In ovarian CSCs, increased expression of DNA polymerase η has been associated with cisplatin resistance and tumor recurrence [92].”
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · eLife · doi:10.7554/elife.112155.1
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · eLife · doi:10.7554/elife.112155
Farrag, M. S., Masoud, R., Hemeda, M. S., Emarah, Z. A., Elnaghi, K., Abdelwahab, K., Farrag, N. S., Ibrahiem, A. T., Ehab, Z., Elrefaie, W. E., et al. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10944-7
“Such data support a role for POLH in treatment tolerance, which may become most relevant under selective pressure from chemotherapy rather than as a sim - ple constitutive marker of tumor aggressiveness (Srivastava et al. 2015; Rocha et al. 2018).”
InfluentialDNA Polymerase Eta Stabilizes Mutant p53 Protein to Increase Tumor Cell Growth
Zhang, J., Shi, Y., & Chen, X. (2026) · Cells · doi:10.3390/cells15201881
Metadata
- Authors
- Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E.
- Affiliations
- Department of Radiology,
- Department of Molecular Virology, Immunology and Medical Genetics,
- Comprehensive Cancer Center,
- Department of Pathology,
- Center for Biostatistics, and
- The Ohio State University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-03-23
- Volume
- 112
- Issue
- 14
- Pages
- 4411-4416
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4394248
- OpenAlex
- W2035233698
- Cited by
- 188
- References
- 51
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 18 · 2022: 16 · 2021: 14 · 2020: 22 · 2019: 18 · 2018: 23 · 2017: 20 · 2016: 20 · 2015: 7
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Health (CA151248)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- DNA polymerase eta, cisplatin resistance, ovarian cancer stem cells, translesion synthesis, chemoresistance, miR-93, apoptosis, tumor recurrence, DNA damage response
- MeSH terms
- Y-Family DNA Polymerases, Animals, Cell Survival, Cisplatin, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, Female, Flow Cytometry, Humans, Mice, Nude, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Transplantation, Ovarian Neoplasms, Recurrence, Neoplastic Stem Cells, Down-Regulation, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.